Document Detail


(18)F-FDG PET in the evaluation of acuity of deep vein thrombosis.
MedLine Citation:
PMID:  23154470     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: F-FDG PET has been used for vascular disease, but its role in deep vein thrombosis (DVT) remains prospectively unexplored.
PATIENTS AND METHODS: Whole-body F-FDG PET/CT scans were performed in patients 1 to 10 weeks after onset of symptomatic DVT (n = 12) and in control subjects without DVT (n = 24). The metabolic activity (SUVmax) of thrombosed and contralateral nonthrombosed vein segments was determined. The sensitivity and specificity of F-FDG PET/CT for the diagnosis of DVT were determined by receiver operating characteristic curve analyses. In 2 patients with DVT, changes in the metabolic activity of thrombosed vein segments in serial F-FDG PET scans.
RESULTS: The metabolic activity in thrombosed veins [SUVmax, 2.41 (0.75)] was visually appreciable and significantly higher than in nonthrombosed veins in either the contralateral extremity of patients with DVT [SUVmax, 1.09 (0.25), P = 0.007] or control subjects [1.21 (0.22), P < 0.001]. The area under the receiver operating characteristic curve for SUVmax was 0.9773 (P < 0.001), indicating excellent accuracy. An SUVmax threshold of greater than 1.645 was 87.5% sensitive and 100% specific for DVT. Metabolic activity in thrombosed veins correlated significantly with time from DVT symptom onset (decrease in SUVmax of 0.02/d, P < 0.05). Best-fit-line analyses suggested that approximately 84 to 91 days after acute DVT, the maximum metabolic activity of thrombosed veins would return to normal levels.
CONCLUSIONS: F-FDG PET/CT is accurate for detecting acute symptomatic, proximal DVT. Metabolic activity in thrombosed veins decreases with time, suggesting that F-FDG PET may be helpful in assessing the age of the clot.
Authors:
Matthew T Rondina; Uyen T Lam; Robert C Pendleton; Larry W Kraiss; Nathan Wanner; Guy A Zimmerman; John M Hoffman; Christopher Hanrahan; Kenneth Boucher; Paul E Christian; Regan I Butterfield; Kathryn A Morton
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Clinical nuclear medicine     Volume:  37     ISSN:  1536-0229     ISO Abbreviation:  Clin Nucl Med     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-16     Completed Date:  2013-04-16     Revised Date:  2013-12-04    
Medline Journal Info:
Nlm Unique ID:  7611109     Medline TA:  Clin Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1139-45     Citation Subset:  IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT01107327
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Male
Middle Aged
Positron-Emission Tomography*
Sensitivity and Specificity
Venous Thrombosis / metabolism,  radionuclide imaging*
Grant Support
ID/Acronym/Agency:
1K23HL092161/HL/NHLBI NIH HHS; 1R01CA121003/CA/NCI NIH HHS; 3P30CA042014/CA/NCI NIH HHS; 5R01HL091754/HL/NHLBI NIH HHS; 5R01HL092746/HL/NHLBI NIH HHS; K23 HL092161/HL/NHLBI NIH HHS; R01 CA121003/CA/NCI NIH HHS; R01CA135556/CA/NCI NIH HHS; R37 HL044525/HL/NHLBI NIH HHS; UL1RR025764/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0Z5B2CJX4D/Fluorodeoxyglucose F18
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ocular Surface Temperature Gradient Is Increased in Eyes with Bacterial Corneal Ulcers.
Next Document:  Increased Adenosine A1 Receptor Levels in Hemianopia Patients After Cerebral Injury: An Application ...